Figure 5 | Cell Death & Disease

Figure 5

From: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

Figure 5

Significant suppression of EGFR and downstream signaling molecules is seen following co-treatment with MPT0E028 and erlotinib. (a) Effect of MPT0E028 and erlotinib on the activity of the EGFR/PI3K/AKT pathway in A549 cells. (b) Co-treatment with erlotinib and MPT0E028 downregulates phospho-EGFR and EGFR protein levels in CL97 and PC9/IR cells. (c) Western blot analysis of the effect of erlotinib/MPT0E028 on IGF-1R, c-met, and HER2 protein expression in A549 cells. Cells were treated with MPT0E028 and/or erlotinib for 72 h, and cell lysates were subjected to immunoblotting using the indicated antibodies

Back to article page